Autoimmunity to ion-channels and other proteins in paraneoplastic disorders

Current Opinion in Immunology

Volumn 8, Issue 6, 1996, Pages 865-871

  Lang, Bethan ^a   Vincent, Angela ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ION CHANNEL; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; AUTOIMMUNITY; NEUROLOGIC DISEASE; PARANEOPLASTIC SYNDROME; PASSIVE IMMUNIZATION; REVIEW;

EID: 0030459321     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(96)80017-3     Document Type: Article

References (55)

1. Posner JB, Dalmau J: Clinical enigmas of paraneoplastic neurologic disorders. Clin Neurol Neurosurg 1995, 97:61-70. A brief review and discussion of the aetiology of the paraneoplastie group of disorders.
2. Darnell RB: Onconeural antigens and the paraneoplastic neurological disorders: at the intersection of cancer, immunity, and the brain. Prac Natl Acad Sci USA 1996, 93:4529-4536. Covers the characterization of onconeural antigens in the CNS and PNS and discusses the possible role of cellular and humoral immune responses underlying paraneoplastic disorders.
3. Moll JWB, Vecht ChJ: Immune diagnosis of paraneoplastic neurological disease. Clin Neurol Neurosurg 1995, 97:71-91. A review of the immunological diagnosis of paraneoplastic disorders of the CNS.
4. Pender M P: Paraneoplastic neurological disorders. In Autoimmune Neurological Disease. Edited by Pender MP, McCombe PA. Cambridge: Cambridge University Press; 1995:327-344. A useful review of the clinical syndromes and of the relevant literature up to 1994.
5. Vincent A: Aetiological factors in development of myasthenia gravis. Adv Neuroimmunol 1994, 4:355-371.
6. S. Willcox N, Schluep M, Ritter M, Schurman HJ, Newsom-Davis j, Christensson B: Myasthenie and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol 1987, 127:447-460.
7. Schluep M, Willcox N, Vincent A, Dhoot GK, Nawsom-Davis J: Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol 1937, 22:212-222.
8. Kaminski HJ, Fenstermaker RA, Abdul-Karim FW, Clayman J, Ruff RL: Acetylcholine receptor subunit gene expression in thymic tissue. Muscle Nerve 1993, 16:1332-1337.
9. Mygland A, Kuwajima G, Mikoshiba K, Tysnes OB, Aarli JA, Gilhus NE: Thymomas express epitopes shared by the ryanodine receptor. J Neuroimmunol 1995, 62:79-63. The presence of an epitope shared by the transmembrane region of tne ryanodine receptor in thymoma tissue was demonstrated by the binding of polyclonal antibodies to synthetic peplides. The epilope was not found in normal thymii nor in other nonmuscle tissues suggesting that it may play a role in inducing anti-ryanodine receptor responses in myasthenia gravis.
10. Marx A, Willisch A, Schultz A, Greiner A, Magi B, Pallini VI, Schalke B, Toyka K, Nix W, Kirchner, Muller-Hermalink H-K: Expression of neurofilaments and of a tttin epitope in thymic epithelial tumours. Implications for a pathogenesis of myasthenia gravis. Am J Pathol 1996, 148:1839-1350. Expression of neurofilaments, including one form that snares epitope(s) with titin, particularly in cortical thymomas, and in the context of potential APCs. The aberrant expression of titin in an inappropriate microenvironment could be the basis of autoimmunity against this antigen, but it fails lo explain antibodies to acetylcholine receptors.
11. Gilhuus NE, Willcox N, Harcaurt G, Nagvekar N, Beeson D, Vincent A, Newsom-Davis J: Antigen presentation by thymoma epithelial cells from myasthenia gravis patients lo potentially pathogenic T cells. J Neuroimmunol 1995, 56:65-76. Cells cultured from myasthenia gravis thymoma tissue were able to present peptide antigens and, to a lesser extent, recombinant antigens to T cell clones specific for acetylcholine receptor peptides. No evidence was found, however, for endogenous antigen presentation.
12. O'Neill JH, Murray NM, Newsom-Davis J: The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988, 111:577-596.
13. 125I-ω-conotoxin MVIIC to label VGCCs was positive in >85% of patients with LEMS, and not in healthy and neurological controls.
14. Lennon VA, Kryzer TJ, Griesrnann G. O'Stilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH: Calcium channel antibodies in the Lambert-Eaton syndrome and other neuroplastic syndromes. N Engl J Med 1995, 332:1467-1474. Simitar results to [13], but the group also reported positive antibody titers in patients with other paraneoplastic disorders and with amyotrophic lateral sclerosis.
15. El Far O, Marqueze B, Leveque C, Martin-Moutot N, Lang B, Newsom-Davis J, Yoshida A, Takahashi M, Seagar M. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenie syndrome. J Neurochem 1995, 64:1696-1702.
16. Leveque C, Hoshino T, David P, Shoji-Kasai Y, Leys K, Omari A, Lang B, El Far O, Sato K, Martin-Moutot N et al.: The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenie syndrome antigen. Proc Natl Acad Scr USA 1992, 89:3625-3629.
17. 7. Takamori M, Takahashi M, Yasukawa Y, Iwasa K, Nemoto Y, Suenaga A, Nagataki S, Nakamura T: Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J Neuroses 1995, 133:95-101.
18. Viglione M P. O'Shaughnessy J, Kirn Yl: Inhibition of calcium currents and exocytosis by Lambert-Eaton syndrome antibodies in human lung cancer cells. J Physiol 1995, 488:303-317. Whole-cell patch clamp recordings were used to demonstrate the presenci of P-type VGCCs on SCLC cell lines, and their inhibition by LEMS IgG.
19. Newsom-Davis J, Lang B: The Lambert Eaton Myasthenic Syndrome. In 'Monography on Myasthenic Disorders'. Edited by Engel AG Philadelphia: FA Davis; 1996, in press.
20. Newsom-Davis J, Mills KR: Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 1993, 116:453-469.
21. Shillito P, Molenaar PC, Vincent A, Leys K, Zhang W, Van der Berg RJ, Plomp JJ, Van Kempen GTH, Chauplannaz G, Winteen AR ef a/.; Acquired myotonia: evidence for autoantlbodies directed against K+ channels of peripheral nerves. Ann Neurol 1995, 38:714-722. A daily injection of IgG derived from patients with acquired neuromyotonia passively transferred electrophysiological defects of the disease to mice, thus indicating the autoimmune basis of the disease. None of the cases m this study were paraneoplastic.
22. Vincent A, Willcox HNA, Roxannis I, Maclennan C, Beeson D, Newsom-Davis J: Thymoma and autoimmune neurological disease: a search for missing links in pathogenesis. In Biological and Clinical Aspects of Thymic Epithelial Tumours. Edited by Muller-Hermelink H-K, Marx A. London: Plenum Press; 1996, in press,
23. Polans AS, Buczylko J, Crabb J, Palczewski K: A photoreceptor calcium binding protein is recognised by autoantibodies obtained from patients with cancer-associated retinopathy. J Cell Biol 1991, 112:981-989.
24. Polans AS, Witkowska D, Haley TL, Amundsen D, Baizer L, Adamjs G: Recoverin, a photoreceptor-specific calcium-binding protein, expressed by the tumour of a patient with cancer-associated retinopathy. Proc Natl Acad Sci USA 1995, 92:9176-9180. Identification of recoverin, a protein involved in the transduction of light in photoreceptors that is also expressed on lung carcinomas derived from pa-tients with cancer-associated retinopathy. It is not found on tumours derived from patients without the syndrome.
25. Lern J, Rannery JG, Li T, Applebury ML, Farber DB, Simon Ml: Retinal degeneration is rescued in transgenic rd mice by expression of the cGMP phosphodiesterase β subunit Proc Natl Acad Sd USA 1992, 89:4422-4426.
26. Jacobson DM, Thirkilt ChE, Tipping SJ: A clinical trial to diagnose paraneoplastic retinopathy. Ann Neurol 1990, 28:162-167.
27. Lennon VA: Paraneoplastic autoantibodies: the case for a descriptive generic nomenclature. Neurology 1994, 44:2236-2240.
28. Dalmau J, Posner JB: Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri). The case for nomenclature based on antibody and antigen specificity. Neurology 1994, 44:2241-2246.
29. Graus F, Elkon KB, Cordon-Cardo G, Posner JB: Sensory neuronopathy and small cell lung cancer. Am J Med 1986, 80:46-52.
30. Dalmaj J, Graus F, Cheung N-KV, Rosenblum MK, Ho A, Canete A, Delattre J-Y, Thompson SJ, Posner JB: Major histocompatibilily proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer 1995, 75:99-109. The compression of MHC class I molecules and trie Hu antigen may play an important role in the development of anti-Hu antibodies, and may contribute to the improved prognosis in patients who develop anti-Hu antibodies. Some children with neuroblastomas have anti-Hu antibodies, and some neuroblastomas express Hu antigen.
31. Manley GT, Smitt PS, Dalmau J Posner JB: Hu antigens: reactivity with Hu antibodies, tumour expression, and major immunogenic sites. Ann Neurol 1995, 38:102-110. Identification of HuD as a human neuronal RNA-binding protein, HuD is also found on small cell lung carcinoma. Two major immunodominant regions appear to play a major role in triggering the anti-Hu immune response.
32. Liu J, Dalmau J, Szabo A, Rasenfeld M, Huber J, Furneaux H: Paraneoplastic encephalomyelitis antigens bind to the AU-rich elements of mRNA. Neurology 1995, 45:544-550.
33. Antoine JC, Honnorat J, Thomas Anterion C, Aguera M, Absi L, Fournel P, Michel D: Limblc encephalitis and immune-logical perturbations in two patients with thymoma. J Neurol Neurosurg Psychiatry 1 995, 58:706-710. The identification of antibodies by imm un oh i stochemistry in two patients with thymoma and CMS symptoms, whose condition improved after removal of the tumours.
34. Peterson K, Rosenblum MK, Kotanides MS, Posner JB: Paraneoplastic cerebellar degeneration. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 1992, 42:1931-1937.
35. Sakai K, Ogasawara T, Hirose G, Jaekle KA, Greenlee JE: Analysis of autoantibody binding to 52-kd paraneoplastic cerebellar degeneration-associated antigen expressed in recombinant proteins. Ann Neurol 1993, 33:373-380.
36. Pohl KRE, Pritchard J, Wilson J: Neurological sequelae of the dancing eye syndrome. Eur J Pediatr 1996, 155:237-244. Comprehensive review of both adult and childhood forms of opsodonus.
37. Fueyo J. Ferrer I, Valldeoriola F, Graus F: The expression of a neuronal nuclear antigen (Ri) recognised by the human anti-Ri autoantibody in the developing rat nervous system. Neurose/ tern 993, 162:141-144.
38. Buckanovich PJ, Yang YYL, Darnell RB: The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 1996, 16:1114-1122. Another RNA-binding paraneoplastic antigen that is expressed in discrete parts of the CNS. Purified antibodies from opsoclonus/myoclonus patients inhibit the binding of RNA in an in vitro assay.
39. Luque FA, Furneaux HM, Ferziger R, Rasenblum MK, Wray SH, Schold SC, Glantz MJ, Jaeckle KA, Biran H, Lesser M et al.: AntiRi: an antibody associated with paraneoplastic opsoclonus and breast cancer. Ann Neurol 1991, 29:241-251.
40. Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P: Autoantibodies to GABA-ergic neurones and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990, 322:1555-1560.
41. Folli F, Solimena M, Cofieli R, Austoni M, Tallini G, Fassetta G, Sates D, Cartlidge N, Bottazzo GF, Piccolo G, De Camilli P: Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 1993, 328:546-551.
42. De Camilla P, Thomas A. Cofiell R, Folli F, Lichte B, Piccolo G, Meinck H-M, Austoni M, Fassetta G, Bottazzo GF et al.: The synaptic vesicle-associated protein amphiphysin is the 128-kO autoantigen of stiff-man syndrome with breast cancer. 1 Exp Med 1993, 178:2219-2223.
43. David C, McPherson PS, Mundigl O, De Camilla P: A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acid Sci USA 1996, 93:331-335. New information regarding the role of amphiphysin (a paraneoplastic antigen in cancer-associated SMS) in endocytosis.
44. Chalk CH, Murray NM, Newsom-Davis J, O'Neill JH, Spiro SG: Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990,40:1552-1556.
45. Grisold W, Drlicek M, Liszka-Satinek U, Wondrusch E: Antitumour therapy in paraneoplastic neurological disease. Clin Neurol Neurosurg 1995, 97:106-111.
46. Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Huassociated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Med Baltimore 1992, 71:59-72.
47. Sillevis Smitt PAE, Manley GT, Posner JB: Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurological disease in mice. Neurology 1995, 45:1873-1873. Immunization of mice, rats and guinea pigs with HuD produces high titres of anti-HuD antibodies but fails to produce the neurological dysfunction.
48. Tanaka M, Tanaka K, Onodera O, Tsuji S: Trial to establish an animal model of paraneoplastic cere bel la r degeneration with anti-Yo antibody. 1. Mouse strains bearing different MHC molecules produce antibodies on immunization with recombinant Yo protein, but do not cause Purkinje cell loss. Clin Neurol Neurosurg 1995, 97:97-100. Active immunization of mice with Yo antigen fails to elicit clinical features of PCD. Similar experiments using passive transfer methods also failed to produce an animal model of the disease.
49. Tanaka K, Tanaka M, Igarashi S, Onodera O, Miyatake T, Tsuji S: Trial to establish an animal model of paraneoplastic cerebellar degeneration with anti-Yo antibody. 2. Passive transfer of miirine mononuclear cells activated with recombinant Yo protein to paraneoplastic cerebellar lymphocytes in severe combined immunodeficiency mice. Clin Neurol Neurosurg 1995, 97:101-105. Experiments attempting to transfer cellular immunity against Yo antigen were unsuccessful.
50. Sakai K, Gofuku M, Kitagawa Y, Ogssawara T, Hirose G: Induction of anti-Purkinje cell antibodies in vivo by immunizing with a recombinant 52-kDa paraneoplastic cerebellar degeneration-associated protein. J Neuroimmunol 1995, 60:135-141. Similar experiment to (48'l, but using recombinant protein PCD17, also failed to elicit a response.
51. Cher LM, Hochberg FH, Teruya J, Nitschke M, Valenzuela RF^ Schmahmann JD, Herbert M, Rosas HD, Stowekll C: Therapy for paraneoplastic neurologic syndromes in six patients with protein A column immunoadsorptlon Cancer 1995, 75:1678-1683.
52. Gahring LC, Twyman RE, Greenlee JE, Rogers SW: Autoantibodies to neuronal glutamate receptors in patients with paraneoplastic neurogenerative syndrome enhance receptor activation. Mol Med 1995, 1:245-253. Demonstration that patients with various paraneoplastic neurological disorders have autoantibodies that bind to and modify the receptor function of different subtypes of the ionotrophic glutamate receptors.
53. Rogers SW, Twyman RE, Gahring LC: The role of autoimmunity to glutamate receptors in neurological disease. Mol Med Today 1996,2:76-81. Review of the role of ionotrophic glutamate receptors and excilotoxicity in diseases of neurological dysfunction.
54. Rogars SW, Andrews PI, Gahring LC, Whisenand T, Cauley K, Crain B, Hughes TE, Heinemann SF, McNamara JO: Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 1994, 265:648-649
55. Nicoletti F, Bruno V, Copani A, Casabona G, Knopfel T: Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? TINS 1996, 19:267-271. Proposed role of metabotrophic glutamate receptors in neurodegenerative disorders.